ArticleWorld journal of surgical oncology2026
Prognostic value of metastatic lymph-node ratio and log-odds of positive nodes after neoadjuvant chemotherapy in breast cancer.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesResidual axillary disease after neoadjuvant chemotherapy (NACT) challenges prognostication with conventional pathologic nodal (ypN) staging, as post-therapy fibrosis and reduced nodal yield can lead to understaging in ypN-positive patients. We aimed to compare the prognostic performance of the metastatic lymph node ratio (mLNR) and the log odds of positive nodes (LODDS) with ypN stage in a homogeneous post-NACT ypN-positive breast cancer cohort, representing, to our knowledge, the first Turkish series to directly contrast these ratio-based metrics in this setting. We compared the prognostic value of the metastatic lymph node ratio (mLNR) and the log odds of positive nodes (LODDS) versus ypN stage in ypN positive breast cancer.
methodsWe retrospectively analyzed 276 stage IIB–III patients (2010–2022) with residual nodal metastasis after NACT and surgery. Survival was evaluated with Kaplan–Meier and Cox models. Discrimination was summarized by AUC (ROC) with 95% CIs; pairwise DeLong tests compared mLNR versus LODDS. Primary analyses treated mLNR/LODDS as continuous variables; cutoff-based sensitivity analyses used 23.7% and − 1.24, respectively. Median follow-up among survivors was 127.7 months.
resultsMedian dissected nodes were 17 (IQR 13–22); median positive nodes were 3. High LODDS ( > − 1.24 vs. ≤ − 1.24) independently associated with shorter DFS (HR 1.69, 95% CI 1.10–2.63; p = 0.017). mLNR and LODDS showed similar, moderate discrimination for OS and DFS; time-dependent AUCs were 0.605 (LODDS) and 0.596 (mLNR) for DFS and 0.618 (LODDS) and 0.620 (mLNR) for OS, with no significant differences by DeLong testing. Classical adverse features (residual breast tumor, triple-negative subtype, grade III) remained independently prognostic.
conclusionsIn ypN-positive disease after NACT, mLNR and LODDS performed at least comparably to ypN stage, offering similar, moderate prognostic discrimination without clear superiority of one metric over the other. They may refine risk estimation as complementary nodal metrics, but subgroup signals are hypothesis-generating and require external validation before any impact on treatment decisions in routine practice; this long-term Turkish post-NACT cohort adds additional evidence to the emerging literature on ratio-based nodal metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.